SMR 2024 | Exploring the role of lifileucel in the treatment of melanoma brain metastases
Allison Betof Warner, MD, Stanford Cancer Center, Stanford, CA, provides a brief overview on lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy for melanoma brain metastases (MBM). The C-144-01 trial (NCT02360579) led to the approval of lifileucel for the treatment of metastatic melanoma, but complications like thrombocytopenia and seizures have been observed in previous studies. A pilot trial (NCT05640193) was designed to combat these complications and explore the feasibility of lifileucel in 10 patients using a modified treatment regimen. This interview took place at the Society for Melanoma Research (SMR) 2024 Annual Meeting in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
